ArticleAACE endocrinology and diabetes
Triphasic Adrenocorticotropic Hormone Dynamics During Immune Checkpoint Inhibitor Therapy in a Patient With Malignant Melanoma.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Immune checkpoint inhibitor (ICI)-related hypophysitis is generally considered to cause irreversible adrenocorticotropic hormone (ACTH) deficiency, requiring long-term glucocorticoid replacement. However, recent reports have described transient ACTH elevation before the onset of adrenal insufficiency. We report a patient with malignant melanoma who developed a previously unreported triphasic pattern of ACTH dynamics during ICI therapy. Case Presentation: A 74-year-old woman was treated with nivolumab monotherapy followed by combination therapy with nivolumab and ipilimumab. She initially presented with ACTH deficiency and an inadequate cortisol response to rapid ACTH stimulation. Plasma ACTH and serum cortisol levels then transiently increased, before declining again and progressing to persistent secondary adrenal insufficiency. Discussion: While transient functional suppression of corticotrophs prior to irreversible structural destruction may partly explain this course, the sequence of ICI exposure is likely to have played an important role in shaping the triphasic ACTH dynamics observed in this case. The temporal pattern of hormonal changes, differences in the typical onset of hypophysitis between antiprogrammed cell death 1 and anti-cytotoxic T-lymphocyte-associated antigen 4 antibodies, and imaging features characteristic of anticytotoxic T-lymphocyte-associated antigen 4-associated hypophysitis support the possibility of layered or overlapping inflammatory insults to the pituitary following sequential ICI exposure. Conclusion: This case highlights that transient ACTH elevation during ICI therapy should not be interpreted as recovery of pituitary function and may precede permanent ACTH deficiency. Careful hormonal monitoring is essential, particularly during sequential or combination ICI therapy. Accumulation of additional cases will help clarify the dynamic pathophysiology of ICI-related hypophysitis and improve clinical monitoring strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.